Related Experiment Video
Updated: Jan 11, 2026

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
Published on: May 11, 2018
[End-of-life decision-making in patients with a ventricular assist device]
Sophie L Gerritse1,2, Maaike van der Graaf3, Jasper J Brugts3
1Reinier de Graaf Gasthuis, afd. Interne Oncologie en Klinische Farmacologie, Delft.
Abstract:
In the Netherlands, approximately 240,000 patients suffer from chronic heart failure, and the incidence is expected to rise in the coming decades. A Left Ventricular Assist Device (LVAD), either temporary or permanent, is increasingly used to treat patients with advanced and end-stage chronic heart failure, with a five-year survival rate exceeding 50%. Healthcare providers in both primary and secondary care will encounter LVAD patients more frequently. Terminal care for LVAD patients requires a specialized approach, with proactive care planning being crucial.
More Related Videos
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Heart Failure VI: Adjunct Therapies
Heart Failure V: Medical Management
Cardiomyopathy II: Dilated Cardiomyopathy
Ethical Dilemmas II
Heart Failure VII: Nursing Interventions

